Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|18|18|2686-2714

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.18, 2011-06, pp. : 2686-2714

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 13, 2016-05 ,pp. : 1413-1426

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) &dgr; and &ggr;

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 8, 2009-05 ,pp. : 738-753

Bentham Science Publishers

Access to resources Recommend Favorite

Computational Medicinal Chemistry to Design Novel Phosphoinositide 3- Kinase (PI3K) Alpha Inhibitors in View of Cancer

By  

Current Bioactive Compounds, Vol. 10, Iss. 3, 2014-08 ,pp. : 147-157

Bentham Science Publishers

Access to resources Recommend Favorite

The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors

By  

Current Cancer Drug Targets, Vol. 8, Iss. 1, 2008-02 ,pp. : 7-18

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

By  

Current Medicinal Chemistry, Vol. 17, Iss. 35, 2010-12 ,pp. : 4326-4341

Bentham Science Publishers

Access to resources Recommend Favorite